Communication
ChemComm
Colorado, 2005, p. 512; ( f ) H. Hu, A. Boone and W. Yang, J. Am. 13 However, the acetyl migration can be suppressed by addition of CAN:
Chem. Soc., 2008, 130, 14493–14503.
2 L. E. Orgel, Crit. Rev. Biochem. Mol. Biol., 2004, 39, 99–123.
3 H. Vorbruggen and C. Ruh-Polenz, Org. React., 1999, 55, 1.
O. P. Chevallier and M. E. Migaud, Beilstein J. Org. Chem., 2006, 2, 14.
14 A. Boto, D. Hernandez, R. Hernandez and E. Alvarez, J. Org. Chem.,
2007, 72, 9523–9532.
4 (a) J. J. Fox, N. Yung and I. Wempan, Biochim. Biophys. Acta, 1957, 23, 15 C. G. Francisco, R. Freire, C. C. Gonzalez, E. I. Leon, C. Riesco-Fagundo
295–305; (b) W. V. Curran and R. B. Angier, Tetrahedron Lett., 1963, and E. Suarez, J. Org. Chem., 2001, 66, 1861–1866.
533–535; (c) W. V. Curran and R. B. Angier, J. Org. Chem., 1966, 31, 16 Crystallographic data for lactone 7 has been deposited with the
201–205.
Cambridge Crystalographic Data Center with CCDC 1034691. This
lactone has been prepared by a different method: M. P. Groziak and
R. Lin, Tetrahedron, 2000, 56, 9885–9893.
5 (a) H. Inoue and T. Ueda, Chem. Pharm. Bull., 1971, 19, 1743–1744;
(b) C. V. Z. Smith, R. K. Robins and R. L. Tolman, J. Org. Chem., 1972,
37, 1418–1422; (c) D. H. Shannahoff and R. A. Sanchez, J. Org. Chem., 17 The reaction of 1-O-acetyl-2,3,5-tri-O-benzoyl-b-D-ribofuranose with
1973, 38, 593–598; (d) A. Holy, Collect. Czech. Chem. Commun., 1975,
40, 738–752; (e) H. Inoue and T. Ueda, Chem. Pharm. Bull., 1978, 26,
2657–2663; ( f ) H. Tanaka, H. Hayakawa and T. Miyasaka, Tetrahe-
dron, 1982, 38, 2635–2642; (g) H. Tanaka, H. Hayakawa, S. Iijima,
methyl orotate (N(3) position was not protected) affords only the
isoorotidine (N(3)-riboside) derivative in 67% yield; see I. A.
Mikhailopulo, E. N. Kalinichenko and A. A. Akhrem, J. Carbohydr.,
Nucleosides, Nucleotides, 1981, 8, 227–260.
K. Haraguchi and T. Miyasaka, Tetrahedron, 1985, 41, 861–866; 18 Orotidine has been converted to uridine. For example see (a) J. P. Ferris
(h) G. Y. Song, F. N. M. Naguib, M. H. e. Kouni and C. K. Chu,
Nucleosides, Nucleotides Nucleic Acids, 2001, 20, 1915–1925;
(i) T. L. Amyes, J. P. Richard and J. J. Tait, J. Am. Chem. Soc., 2005,
127, 15708–15709.
and P. C. Joshi, Science, 1978, 201, 361–362; (b) J. P. Ferris and
P. C. Joshi, J. Org. Chem., 1979, 44, 2133–2137. For an alternative
approach to pyrimidine nucleosides see (c) M. W. Powner, B. Gerland
and J. D. Sutherland, Nature, 2009, 459, 239–242.
6 For example see A. M. Bello, E. Poduch, Y. Liu, L. Wei, I. Crandall, 19 (a) J. G. Wittmann, D. Heinrich, K. Gasow, A. Frey, U. Diederichsen
X. Wang, C. Dayanand, K. C. Kain, E. F. Pai and L. P. Kotra, J. Med.
Chem., 2008, 51, 439–448.
7 (a) B. E. Maryanoff, A. B. Reitz and S. O. Nortey, Tetrahedron, 1988,
and M. G. Rudolph, Structure, 2008, 16, 82–92; (b) L. Quemeneur,
L. Beloeil, M. C. Michallet, G. Angelov, M. Tomkowiak, J. P. Revillard
and J. Marvel, J. Immunol., 2004, 173, 4945–4952.
44, 3093–3106; (b) L. N. Beigelman and S. N. Mikhailov, Carbohydr. 20 For examples see (a) D. F. Smee, P. A. McKernan, L. D. Nord,
Res., 1990, 203, 324–329; (c) T.-C. Chien and J.-W. Chern, Carbohydr.
Res., 2004, 339, 1215–1217.
8 (a) L. O. Ross, L. Goodman and B. R. Baker, J. Org. Chem., 1960, 25,
1950–1953; (b) H. Gershon, J. Org. Chem., 1962, 27, 3507–3510.
9 (a) D. G. Crosby and R. V. Berthold, J. Med. Chem., 1963, 6, 334–335;
(b) J.-S. Ti, A. S. Steinfeld, F. Naider, A. Gulumoglu, S. V. Lewis and
R. C. Willis, C. R. Petrie, T. M. Riley, G. R. Revankar, R. K. Robins
and R. A. Smith, Antimicrob. Agents Chemother., 1987, 31, 1535–1541;
(b) Q.-Y. Wang, S. Bushell, M. Qing, H. Y. Xu, A. Bonavia, S. Nunes,
J. Zhou, M. K. Poh, P. F. Sessions, P. Niyomrattanakit, H. Dong,
K. Hoffmaster, A. Goh, S. Nilar, W. Schul, S. Jones, L. Kramer,
T. Compton and P.-Y. Shis, J. Virol., 2011, 85, 6548–6556.
J. M. Becker, J. Med. Chem., 1980, 23, 913–918; (c) F. Hausch and 21 (a) A. C. Allison, Immunopharmacology, 2000, 47, 63–83; (b) M. L.
A. Jaschke, Tetrahedron, 2001, 57, 1261–1268.
Herrmann, R. Schleyerbach and B. J. Kirschbaum, Immunopharmacology,
2000, 47, 273–289; (c) G. Weber, Biochemistry, 2001, 66, 1164–1173;
(d) R. I. Christopherson, S. D. Lyons and P. K. Wilson, Acc. Chem. Res.,
2002, 35, 961–971; (e) E. Chu, M. A. Callender, M. P. Farrell and
J. C. Schmitz, Cancer Chemother. Pharmacol., 2003, 52, 80–89.
10 (a) Y. Mizuno, C. Kaneko, Y. Oikawa, T. Ikeda and T. Itoh, J. Am.
Chem. Soc., 1972, 94, 4737–4739; (b) M. E. Jung and C. Castro, J. Org.
Chem., 1993, 58, 807–808; (c) B. H. Lipshutz, H. Hayakawa, K. Kato,
R. F. Lowe and K. L. Stevens, Synthesis, 1994, 1476–1484;
(d) K. Sujino and H. Sugimura, Tetrahedron Lett., 1994, 35, 22 (a) S. R. Krungkrai, S. Aoki, N. M. Palacpac, D. Sato, T. Mitamura,
1883–1886; (e) X. Xia, J. Wang, M. W. Hager, N. Sisti and
D. C. Liotta, Tetrahedron Lett., 1997, 38, 1111–1114.
11 B. Kaskar, G. L. Heise, R. S. Michalak and B. R. Vishnuvajjala,
Synthesis, 1990, 1031–1032.
12 C. G. Francisco, C. G. Martin and E. Suarez, J. Org. Chem., 1998, 63,
2099–2109.
J. Krungkrai and T. Horii, Mol. Biochem. Parasitol., 2004, 134,
245–255; (b) J. Baldwin, C. H. Michnoff, N. A. Malmquist, J. White,
M. G. Roth, P. K. Rathod and M. A. Phillips, J. Biol. Chem., 2005, 280,
21847–21853; (c) S. R. Krungkrai, B. J. DelFraino, J. A. Smiley,
P. Prapunwattana, T. Mitamura, T. Horii and J. A. Krungkrai,
Biochemistry, 2005, 44, 1643–1652.
This journal is ©The Royal Society of Chemistry 2015
Chem. Commun., 2015, 51, 5618--5621 | 5621